TY - JOUR A1 - Antoniou, Antonis C. A1 - Kuchenbaecker, Karoline B. A1 - Soucy, Penny A1 - Beesley, Jonathan A1 - Chen, Xiaoqing A1 - McGuffog, Lesley A1 - Lee, Andrew A1 - Barrowdale, Daniel A1 - Healey, Sue A1 - Sinilnikova, Olga M. A1 - Caligo, Maria A. A1 - Loman, Niklas A1 - Harbst, Katja A1 - Lindblom, Annika A1 - Arver, Brita A1 - Rosenquist, Richard A1 - Karlsson, Per A1 - Nathanson, Kate A1 - Domchek, Susan A1 - Rebbeck, Tim A1 - Jakubowska, Anna A1 - Lubinski, Jan A1 - Jaworska, Katarzyna A1 - Durda, Katarzyna A1 - Zlowowcka-Perłowska, Elżbieta A1 - Osorio, Ana A1 - Durán, Mercedes A1 - Andrés, Raquel A1 - Benítez, Javier A1 - Hamann, Ute A1 - Hogervorst, Frans B. A1 - van Os, Theo A. A1 - Verhoef, Senno A1 - Meijers-Heijboer, Hanne E. J. A1 - Wijnen, Juul A1 - Garcia, Encarna B. Gómez A1 - Ligtenberg, Marjolijn J. A1 - Kriege, Mieke A1 - Collée, Margriet A1 - Ausems, Margreet G. E. M. A1 - Oosterwijk, Jan C. A1 - Peock, Susan A1 - Frost, Debra A1 - Ellis, Steve D. A1 - Platte, Radka A1 - Fineberg, Elena A1 - Evans, D. Gareth A1 - Lalloo, Fiona A1 - Jacobs, Chris A1 - Eeles, Ros A1 - Adlard, Julian A1 - Davidson, Rosemarie A1 - Cole, Trevor A1 - Cook, Jackie A1 - Paterson, Joan A1 - Douglas, Fiona A1 - Brewer, Carole A1 - Hodgson, Shirley A1 - Morrison, Patrick J. A1 - Walker, Lisa A1 - Rogers, Mark T. A1 - Donaldson, Alan A1 - Dorkins, Huw A1 - Godwin, Andrew K. A1 - Bove, Betsy A1 - Stoppa-Lyonnet, Dominique A1 - Houdayer, Claude A1 - Buecher, Bruno A1 - de Pauw, Antoine A1 - Mazoyer, Sylvie A1 - Calender, Alain A1 - Léoné, Mélanie A1 - Bressac-de Paillerets, Brigitte A1 - Caron, Olivier A1 - Sobol, Hagay A1 - Frenay, Marc A1 - Prieur, Fabienne A1 - Ferrer, Sandra Fert A1 - Mortemousque, Isabelle A1 - Buys, Saundra A1 - Daly, Mary A1 - Miron, Alexander A1 - Terry, Mary Beth A1 - Hopper, John L. A1 - John, Esther M. A1 - Southey, Melissa A1 - Goldgar, David A1 - Singer, Christian F. A1 - Fink-Retter, Anneliese A1 - Muy-Kheng, Tea A1 - Geschwantler Kaulich, Daphne A1 - Hansen, Thomas V. O. A1 - Nielsen, Finn C. A1 - Barkardottir, Rosa B. A1 - Gaudet, Mia A1 - Kirchhoff, Tomas A1 - Joseph, Vijai A1 - Dutra-Clarke, Ana A1 - Offit, Kenneth A1 - Piedmonte, Marion A1 - Kirk, Judy A1 - Cohn, David A1 - Hurteau, Jean A1 - Byron, John A1 - Fiorica, James A1 - Toland, Amanda E. A1 - Montagna, Marco A1 - Oliani, Cristina A1 - Imyanitov, Evgeny A1 - Isaacs, Claudine A1 - Tihomirova, Laima A1 - Blanco, Ignacio A1 - Lazaro, Conxi A1 - Teulé, Alex A1 - Del Valle, J. A1 - Gayther, Simon A. A1 - Odunsi, Kunle A1 - Gross, Jenny A1 - Karlan, Beth Y. A1 - Olah, Edith A1 - Teo, Soo-Hwang A1 - Ganz, Patricia A. A1 - Beattie, Mary S. A1 - Dorfling, Cecelia M. A1 - Jansen van Rensburg, Elizabeth A1 - Diez, Orland A1 - Kwong, Ava A1 - Schmutzler, Rita K. A1 - Wappenschmidt, Barbara A1 - Engel, Christoph A1 - Meindl, Alfons A1 - Ditsch, Nina A1 - Arnold, Norbert A1 - Heidemann, Simone A1 - Niederacher, Dieter A1 - Preisler-Adams, Sabine A1 - Gadzicki, Dorothea A1 - Varon-Mateeva, Raymonda A1 - Deissler, Helmut A1 - Gehrig, Andrea A1 - Sutter, Christian A1 - Kast, Karin A1 - Fiebig, Britta A1 - Schäfer, Dieter A1 - Caldes, Trinidad A1 - de la Hoya, Miguel A1 - Nevanlinna, Heli A1 - Muranen, Taru A. A1 - Lespérance, Bernard A1 - Spurdle, Amanda B. A1 - Neuhausen, Susan L. A1 - Ding, Yuan C. A1 - Wang, Xianshu A1 - Fredericksen, Zachary A1 - Pankratz, Vernon S. A1 - Lindor, Noralane M. A1 - Peterlongo, Paulo A1 - Manoukian, Siranoush A1 - Peissel, Bernard A1 - Zaffaroni, Daniela A1 - Bonanni, Bernardo A1 - Bernard, Loris A1 - Dolcetti, Riccardo A1 - Papi, Laura A1 - Ottini, Laura A1 - Radice, Paolo A1 - Greene, Mark H. A1 - Loud, Jennifer T. A1 - Andrulis, Irene L. A1 - Ozcelik, Hilmi A1 - Mulligan, Anna Marie A1 - Glendon, Gord A1 - Thomassen, Mads A1 - Gerdes, Anne-Marie A1 - Jensen, Uffe B. A1 - Skytte, Anne-Bine A1 - Kruse, Torben A. A1 - Chenevix-Trench, Georgia A1 - Couch, Fergus J. A1 - Simard, Jacques A1 - Easton, Douglas F. T1 - Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers JF - Breast Cancer Research N2 - Introduction: Several common alleles have been shown to be associated with breast and/or ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Recent genome-wide association studies of breast cancer have identified eight additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2). Methods: To evaluate whether these single nucleotide polymorphisms (SNPs) are associated with breast cancer risk for BRCA1 and BRCA2 carriers, we genotyped these SNPs in 12,599 BRCA1 and 7,132 BRCA2 mutation carriers and analysed the associations with breast cancer risk within a retrospective likelihood framework. Results: Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 x 10\(^{-4}\)). The association was restricted to mutations proven or predicted to lead to absence of protein expression (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3.1 x 10\(^{-5}\), P-difference = 0.03). Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df P = 0.007; rs1292011 2df P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 x 10\(^{-5}\)) and there was marginal evidence of association with ER- negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049). Conclusions: The present findings, in combination with previously identified modifiers of risk, will ultimately lead to more accurate risk prediction and an improved understanding of the disease etiology in BRCA1 and BRCA2 mutation carriers. KW - investigators KW - genetic modifiers KW - mammographic density KW - susceptibility loci KW - ovarian cancer KW - hormone-related protein KW - genome-wide association KW - tumor subtypes KW - alleles KW - consortium Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130449 VL - 14 IS - R33 ER - TY - JOUR A1 - Zirkel, J. A1 - Cecil, A. A1 - Schäfer, F. A1 - Rahlfs, S. A1 - Ouedraogo, A. A1 - Xiao, K. A1 - Sawadogo, S. A1 - Coulibaly, B. A1 - Becker, K. A1 - Dandekar, T. T1 - Analyzing Thiol-Dependent Redox Networks in the Presence of Methylene Blue and Other Antimalarial Agents with RT-PCR-Supported in silico Modeling JF - Bioinformatics and Biology Insights N2 - BACKGROUND: In the face of growing resistance in malaria parasites to drugs, pharmacological combination therapies are important. There is accumulating evidence that methylene blue (MB) is an effective drug against malaria. Here we explore the biological effects of both MB alone and in combination therapy using modeling and experimental data. RESULTS: We built a model of the central metabolic pathways in P. falciparum. Metabolic flux modes and their changes under MB were calculated by integrating experimental data (RT-PCR data on mRNAs for redox enzymes) as constraints and results from the YANA software package for metabolic pathway calculations. Several different lines of MB attack on Plasmodium redox defense were identified by analysis of the network effects. Next, chloroquine resistance based on pfmdr/and pfcrt transporters, as well as pyrimethamine/sulfadoxine resistance (by mutations in DHF/DHPS), were modeled in silico. Further modeling shows that MB has a favorable synergism on antimalarial network effects with these commonly used antimalarial drugs. CONCLUSIONS: Theoretical and experimental results support that methylene blue should, because of its resistance-breaking potential, be further tested as a key component in drug combination therapy efforts in holoendemic areas. KW - methylene blue KW - malaria KW - elementary mode analysis KW - drug KW - resistance KW - combination therapy KW - pathway KW - metabolic flux Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123751 N1 - This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. VL - 6 ER - TY - JOUR A1 - Alepee, Natalie A1 - Bahinski, Anthony A1 - Daneshian, Mardas A1 - De Weyer, Bart A1 - Fritsche, Ellen A1 - Goldberg, Alan A1 - Hansmann, Jan A1 - Hartung, Thomas A1 - Haycock, John A1 - Hogberg, Helena T. A1 - Hoelting, Lisa A1 - Kelm, Jens M. A1 - Kadereit, Suzanne A1 - McVey, Emily A1 - Landsiedel, Robert A1 - Leist, Marcel A1 - Lübberstedt, Marc A1 - Noor, Fozia A1 - Pellevoisin, Christian A1 - Petersohn, Dirk A1 - Pfannenbecker, Uwe A1 - Reisinger, Kerstin A1 - Ramirez, Tzutzuy A1 - Rothen-Rutishauser, Barbara A1 - Schäfer-Korting, Monika A1 - Zeilinger, Katrin A1 - Zurich, Marie-Gabriele T1 - State-of-the-Art of 3D Cultures (Organs-on-a-Chip) in Safety Testing and Pathophysiology JF - ALTEX - Alternatives to Animal Experimentation N2 - Integrated approaches using different in vitro methods in combination with bioinformatics can (i) increase the success rate and speed of drug development; (ii) improve the accuracy of toxicological risk assessment; and (iii) increase our understanding of disease. Three-dimensional (3D) cell culture models are important building blocks of this strategy which has emerged during the last years. The majority of these models are organotypic, i.e., they aim to reproduce major functions of an organ or organ system. This implies in many cases that more than one cell type forms the 3D structure, and often matrix elements play an important role. This review summarizes the state of the art concerning commonalities of the different models. For instance, the theory of mass transport/metabolite exchange in 3D systems and the special analytical requirements for test endpoints in organotypic cultures are discussed in detail. In the next part, 3D model systems for selected organs liver, lung, skin, brain are presented and characterized in dedicated chapters. Also, 3D approaches to the modeling of tumors are presented and discussed. All chapters give a historical background, illustrate the large variety of approaches, and highlight up- and downsides as well as specific requirements. Moreover, they refer to the application in disease modeling, drug discovery and safety assessment. Finally, consensus recommendations indicate a roadmap for the successful implementation of 3D models in routine screening. It is expected that the use of such models will accelerate progress by reducing error rates and wrong predictions from compound testing. KW - 3D models KW - organotypic KW - organ-on-a-chip KW - multicellular tumor spheroids KW - primary human hepatocytes KW - embryonic stem cell KW - reconstructed human epidermis KW - in-vitro models KW - full thickness skin KW - necrosis-factor-alpha KW - metabolic flux analysis KW - long-term KW - human liver cells Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117826 VL - 31 IS - 4 ER - TY - JOUR A1 - Stölzel, F. A1 - Mohr, B. A1 - Kramer, M. A1 - Oelschlägel, U. A1 - Bochtler, T. A1 - Berdel, W. E. A1 - Kaufmann, M. A1 - Baldus, C. D. A1 - Schäfer-Eckart, K. A1 - Stuhlmann, R. A1 - Einsele, H. A1 - Krause, S. W. A1 - Serve, H. A1 - Hänel, M. A1 - Herbst, R. A1 - Neubauer, A. A1 - Sohlbach, K. A1 - Mayer, J. A1 - Middeke, J. M. A1 - Platzbecker, U. A1 - Schaich, M. A1 - Krämer, A. A1 - Röllig, C. A1 - Schetelig, J. A1 - Bornhäuser, M. A1 - Ehninger, G. T1 - Karyotype complexity and prognosis in acute myeloid leukemia JF - Blood Cancer Journal N2 - A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p21∼22;q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with 4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9;11)(p21∼22;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype. KW - Cancer genetics KW - Genetics research Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164530 VL - 6 ER - TY - JOUR A1 - Röllig, C. A1 - Kramer, M. A1 - Gabrecht, M. A1 - Hänel, M. A1 - Herbst, R. A1 - Kaiser, U. A1 - Schmitz, N. A1 - Kullmer, J. A1 - Fetscher, S. A1 - Link, H. A1 - Mantovani-Löffler, L. A1 - Krümpelmann, U. A1 - Neuhaus, T. A1 - Heits, F. A1 - Einsele, H. A1 - Ritter, B. A1 - Bornhäuser, M. A1 - Schetelig, J. A1 - Thiede, C. A1 - Mohr, B. A1 - Schaich, M. A1 - Platzbecker, U. A1 - Schäfer-Eckart, K. A1 - Krämer, A. A1 - Berdel, W. E. A1 - Serve, H. A1 - Ehninger, G. A1 - Schuler, U. S. T1 - Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients JF - Annals of Oncology N2 - Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7+3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA). Patients and methods: Patients with newly diagnosed AML>60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m(2) twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m(2) days 1-3) (IMA) or standard induction therapy with cytarabine (100 mg/m(2) continuously days 1-7) plus daunorubicin (45 mg/m(2) days 3-5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone. Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33-45] versus 55% (95% CI: 49-61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513). Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients. KW - acute myeloid leukemia KW - cytarabine dose KW - elderly Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226473 VL - 29 IS - 4 ER - TY - JOUR A1 - Wagner, N. A1 - Crippa, L. A1 - Amaricci, A. A1 - Hansmann, P. A1 - Klett, M. A1 - König, E. J. A1 - Schäfer, T. A1 - Di Sante, D. A1 - Cano, J. A1 - Millis, A. J. A1 - Georges, A. A1 - Sangiovanni, G. T1 - Mott insulators with boundary zeros JF - Nature Communications N2 - The topological classification of electronic band structures is based on symmetry properties of Bloch eigenstates of single-particle Hamiltonians. In parallel, topological field theory has opened the doors to the formulation and characterization of non-trivial phases of matter driven by strong electron-electron interaction. Even though important examples of topological Mott insulators have been constructed, the relevance of the underlying non-interacting band topology to the physics of the Mott phase has remained unexplored. Here, we show that the momentum structure of the Green’s function zeros defining the “Luttinger surface" provides a topological characterization of the Mott phase related, in the simplest description, to the one of the single-particle electronic dispersion. Considerations on the zeros lead to the prediction of new phenomena: a topological Mott insulator with an inverted gap for the bulk zeros must possess gapless zeros at the boundary, which behave as a form of “topological antimatter” annihilating conventional edge states. Placing band and Mott topological insulators in contact produces distinctive observable signatures at the interface, revealing the otherwise spectroscopically elusive Green’s function zeros. KW - electronic properties and materials KW - topological insulators Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-358150 VL - 14 ER - TY - JOUR A1 - Gratwohl, A A1 - Pfirrmann, M A1 - Zander, A A1 - Kröger, N A1 - Beelen, D A1 - Novotny, J A1 - Nerl, C A1 - Scheid, C A1 - Spiekermann, K A1 - Mayer, J A1 - Sayer, HG A1 - Falge, C A1 - Bunjes, D A1 - Döhner, H A1 - Ganser, A A1 - Schmidt-Wolf, I A1 - Schwerdtfeger, R A1 - Baurmann, H A1 - Kuse, R A1 - Schmitz, N A1 - Wehmeier, A A1 - Fischer, J Th A1 - Ho, AD A1 - Wilhelm, M A1 - Goebeler, M-E A1 - Lindemann, HW A1 - Bormann, M A1 - Hertenstein, B A1 - Schlimok, G A1 - Baerlocher, GM A1 - Aul, C A1 - Pfreundschuh, M A1 - Fabian, M A1 - Staib, P A1 - Edinger, M A1 - Schatz, M A1 - Fauser, A A1 - Arnold, R A1 - Kindler, T A1 - Wulf, G A1 - Rosselet, A A1 - Hellmann, A A1 - Schäfer, E A1 - Prümmer, O A1 - Schenk, M A1 - Hasford, J A1 - Heimpel, H A1 - Hossfeld, DK A1 - Kolb, H-J A1 - Büsche, G A1 - Haferlach, C A1 - Schnittger, S A1 - Müller, MC A1 - Reiter, A A1 - Berger, U A1 - Saußele, S A1 - Hochhaus, A A1 - Hehlmann, R T1 - Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment JF - Leukemia N2 - Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69–0.82) vs 0.69 (95% CI: 0.61–0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high- (P<0.001) and non-high-risk disease (P=0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56% vs 39%; P = 0.005) and free of drug treatment (56% vs 6%; P<0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered. KW - chronic myeloid leukemia KW - stem cell transplantation KW - drug treatment KW - CML KW - tyrosine kinase inhibitors KW - allogeneic hematopoietic stem cell transplantation Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-150368 VL - 30 ER -